Uniqsis reports on two major orders for its FlowSyn™ flow chemistry systems from organizations involved with the South African Pharmaceutical Industry.
In the pharmaceutical sector, industry growth in the emerging world is rapidly outpacing mature markets like Europe and the US. Although at present the pharma industries across Africa account for just 2% of the global medicines market, the sector's rapid growth is predicted to be a source of immense societal benefit, both economic and medical.
Steve Evans, Commercial Director at Uniqsis said:
The first of our 2 large FlowSyn system orders was received in February 2019 from the Council for Scientific and Industrial Research (CSIR) as part of a focused pharmaceutical technology innovation area which will form part of a new chemistry division that is being established. This world class research and development group will be focusing on doing semi-scale up work (100 g to 1 Kg) on some existing flow process routes.”
Mr Evans added:
The second order was recently received from the highly respected Department of Chemistry at the University of Pretoria as a result of them obtaining high-end infrastructure funding for an automated flow reactor scale up system to support pharmaceutical R&D.”
Flow chemistry in micro-reactors has many advantages over batch processing notably better reproducibility and scalability, improved yields and fewer problems with unstable intermediates or exothermic reactions. The FlowSyn™ range of integrated, flow reactor systems from Uniqsis is widely proven to handle everything from homogeneous single reactions to complex, multi-reagent reactions. A range of optional gas addition, microwave, low temperature and binary pump (4-channel) modules further enhance the operational versatility of the FlowSyn system.